BIM-IOL System
Glaucoma (Open-Angle) & Cataracts; Ocular Hypertension (OHT) & Cataracts
Phase 3Active, under clinical development
Key Facts
Indication
Glaucoma (Open-Angle) & Cataracts; Ocular Hypertension (OHT) & Cataracts
Phase
Phase 3
Status
Active, under clinical development
Company
About SpyGlass Pharma
SpyGlass Pharma is developing a transformative solution for the concurrent treatment of glaucoma and cataracts, two leading causes of vision loss. Its proprietary BIM-IOL System combines a standard monofocal intraocular lens with non-bioerodible drug-eluting pads that release bimatoprost directly into the eye for up to three years. This approach aims to eliminate the need for daily eye drops, overcoming the major challenge of patient non-adherence. By integrating therapy into a common surgical procedure, SpyGlass seeks to enable all cataract surgeons to treat glaucoma, potentially expanding access to effective, long-term intraocular pressure control.
View full company profile